New Ray Medicine International Holding Ltd
06108
Company Profile
Business description
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
Contact
19 Dangui Road
B-C, 37th Floor, Dikai International Center
Hangzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Pharmaceutical Retailers
Fiscal Year End
31 December 2026
Employees
30
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
Demographic challenges in A2’s largest market lead to sell-off.
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,058.91 | 3.67 | -0.05% |
| DAX 40 | 24,641.04 | 62.08 | -0.25% |
| Dow JONES (US) | 48,488.59 | 870.74 | -1.76% |
| FTSE 100 | 10,125.32 | 1.46 | -0.01% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 22,954.32 | 561.07 | -2.39% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,796.86 | 143.15 | -2.06% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |